|
Current Human Immune Therapy Center clinical trials for melanoma are listed below with a link to either our webpage or a National Cancer Institute webpage. The link will provide you with a description of the trial.
View publications related to our melanoma clinical trials.
For more information about our melanoma trials,
contact Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Trials for Patients with Metastatic Disease
(resected melanoma) |
Mel 48 trial (for patients with Stage IIB-IV melanoma)
A Multipeptide Vaccine in Melanoma Patients with Evaluation of the Injection Site Microenvironment
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Mel 46 trial (for patients with unresectable stage III or IV melanoma)
Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction with Paclitaxel in Patients with Advanced Melanoma
Contact: Jonni Thoma, Phone:(434)982-6714, E-mail: mjh4a@virginia.edu.
Mel 47 trial (for patients with unresectable stage III or stage IV melanoma)
A Phase 2 Study of CCI-779 in Combination with Bevacizumab in Stage III or IV Melanoma
There is additional information about this trial at the National Cancer Institute web site.
Contact: Jonni Thoma, Phone: (434)982-6714, E-mail: mjh4a@virginia.edu.
Trial Summaries 
Mel 48 trial
Title: A Multipeptide Vaccine in Melanoma Patients with Evaluation of the Injection Site Microenvironment
Principal Investigator: Craig L. Slingluff, Jr., MD
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu
Trial Summary
UVA Health System, Human Immune Therapy Center seeks participants with Stage IIB-IV melanoma for a research study.
The purpose of this study is to identify what goes on with cells at the site where an experimental vaccine is given, in order to improve the usefulness of cancer vaccines. Participants will undergo CT and MRI scans, have physical examinations, answer questions regarding medical history, receive an experimental vaccine, undergo a biopsy of the injection site, and have urine and blood tests as part of this study.
There will be 11 study visits over 32 weeks. All participants will receive 6 vaccines over 7 weeks in a primary vaccine site. Participants will be randomly assigned to 1 of 2 study treatment groups which determine the make-up of the vaccine that will be given in a second vaccine site called the replicate vaccine site. Within each study treatment group, participants will also be randomly assigned to 1 of 5 sub-groups to determine the number of replicate vaccine injections they will receive (0, 1, 3, or 6) and the day a piece of skin at the replicate vaccine site will be removed (biopsy) to study the cells in the laboratory (Day 1, 8, 22, 50, or 85). Participants will be asked to complete a symptom diary to monitor the effects to the treatments.
Participant or participant's insurance will be responsible for the cost of some required procedures. There is no compensation available for participants in this study. IRB-HSR #13498
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Mel 46 trial
Title: Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction with Paclitaxel in Patients with Advanced Melanoma
Principal Investigator: William Grosh, MD
Contact: Jonni Thoma, Phone:(434)982-6714, E-mail: mjh4a@virginia.edu.
Trial Summary
The University of Virginia Health System's Cancer Center seeks adult participants with advanced melanoma for a research study.
If you decide to participate in this study, you will receive paclitaxel and GMCSF given in cycles of 21 days. Each cycle is one day of paclitaxel, 14 days of GMCSF, and 4 days of rest. Participants may receive up to 12 cycles of study drugs. Treatment will be at the UVA Cancer Center and some will be administered in your home. Your blood will be drawn and tested at the UVA GCRC.
There will be up to 23 visits in 9 months. Participants will then come in every 3 months for a total of 3 years. Each visit will last up to 3 hours.
Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.
Trial Calendar Click to view and print the calendar for this trial.
Screening Tests Click to view and print the screening tests for this trial.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Mel 47 trial
Title: A Phase 2 Study of CCI-779 in Combination with Bevacizumab in Stage III or IV Melanoma (Mel 47)
Principal Investigator: Craig Slingluff, MD
Contact: Jonni Thoma, Phone: (434)982-6714, E-mail: mjh4a@virginia.edu.
Trial Summary
The Human Immune Therapy Center of the Cancer Center at The University of Virginia Health System seeks adults with melanoma for a research study.
The purpose of this study is to find out what effects drugs CCI-779 and bevacizumab have on participants with melanoma. CCI-779 is an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma or in any other cancer. Bevacizumab is also an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma.
Participants will undergo CT, MRI, and bone scans, physical examinations, biopsies, answer questions regarding medical history, have an EKG, and have urine and blood tests as part of this study. Participants will undergo as many as 26 cycles of treatment (each cycle lasts 14 days; thus, up to one year of treatment). Each cycle consists of infusions on days 1, 8, and may also include scans, physical exams, blood tests, and tumor and normal skin biopsies. Treatments will take place in the UVA Health System Cancer Center. Two overnight visits in the General Clinical Research Center at the UVA Health System are required. After completing study treatments, participants will have a 30-day follow-up visit with the doctor, and continue follow-up every three months for two years.
Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.
Consent form Click to view and print the consent form for this trial.
Contact: Jonni Thoma, Phone: (434)982-6714, E-mail: mjh4a@virginia.edu.
|
